LEADERSHIP

Home LEADERSHIP

KALIVIR is led by an experienced team of experts that have pioneered the field of oncolytic viral immunotherapy for decades. The leadership team’s experience spans across all stages of oncolytic virus development from discovery and translation to global Phase 3 clinical trial and business development. We are also supported by world-renowned scientific and clinical advisors that will help guide the development of our programs.

LEADERSHIP

HELENA CHAYE, Ph.D., J.D.

Chief Executive Officer

STEPHEN H. THORNE, Ph.D.

Chief Scientific Officer

JAMES M. BURKE, M.D.

Chief Medical Officer

SCHOND GREENWAY

Chief Financial Officer

URSULA FRITSCH, PharmD

Chief Regulatory Officer

ADINA PELUSIO

Chief Development Officer

PAUL YOUM

Vice President, Corporate Development and Alliance Management

Board of Directors

HELENA CHAYE, Ph.D., J.D.
Chief Executive Officer

Helena has over 23 years of experience in the biotechnology industry having held leadership positions in operations, corporate affairs, business development and IP management primarily in oncolytic virotherapy development. Most recently, Helena served as Chief Business Officer at SillaJen Biotherapeutics, Inc. where she managed all operations including corporate and business development strategies, R&D strategy and intellectual property. Prior to joining SillaJen, Helena held the positions of VP of Corporate Affairs & IP at Jennerex Biotherapeutics and the Director of Business Development at MediGene. Helena received her B.S. in Biochemistry and her Ph.D. in Genetics from the University of British Columbia and her J.D. from Dalhousie University.

SCHOND GREENWAY
Chief Financial Officer

Schond Greenway joined KaliVir Immunotherapeutics as Chief Financial Officer (CFO) in August 2024. He brings over 25 years of experience in corporate finance and investment analysis, with deep expertise in the life sciences and financial services sectors, particularly in capital markets and corporate financial transactions. Before KaliVir, Schond served as CFO at MindMed (MNMD), where he was responsible for all aspects of corporate finance, investor relations, public relations, and information technology. Before that, he held the CFO position at Avalo Therapeutics (AVTX). Earlier in his career, he held executive leadership roles at Mesoblast Ltd (MESO), Halozyme Therapeutics (HALO), and DURECT Corporation (DRRX). His investment banking career began at Morgan Stanley, and he later became Vice President, Healthcare Desk Analyst at Barclays Capital.

STEPHEN H. THORNE, Ph.D.
Chief Scientific Officer

Stephen Thorne co-founded Kalivir in 2019 and currently serves as Chief Scientific Officer. He is a leader in the field of oncolytic viral immunotherapy and previously co-founded Western Oncolytics, BioEclipse and Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials. Stephen was a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London. Stephen has served in post doctorate roles at Surrey University, Cancer Research UK, and Stanford University and has authored more than 100 scientific publications in the field.

RICHARD JONES, M.B.A.
Director

Rick Jones is a seasoned executive and serves on the board of several companies in addition to Western Oncolytics, including Pegasystems, Inc. and Colo5 LLC. He was a former President, COO, and Vice Chairman at Pegasystems. Rick has positions of Chief Executive Officer of Fleet Investment Services, Inc., Executive Vice President for FMR LLC, Principal at Booz Allen Hamilton, Inc., European Head at Hewitt Associates, Inc. and Member-Operating Committee at Barnett Banks, Inc.

Rick holds an M.B.A. from Wharton School of the University of Pennsylvania and a B.S. from Duke University.

TOM LEONARD
Director

Tom Leonard is a serial entrepreneur with a successful track record of founding and leading companies in the tech space. In addition to Western Oncolytics, he serves on the boards of Caretta Data and DMEautomotive. Previously, Tom was COO and CIO of DMEautomotive.

He has also co-founded and led several ventures including Clear Voice Research, Red Rocket Solutions, Encore Development, and TML Systems. Early in his career, Tom was a General Manager at Symantec and a Software Architect at Harris Corporation. He holds an M.S. and B.S. in Computer Sciences from Florida State University.

JON WIGGINTON, M.D.
Director

Jon Wigginton, M.D. served as the Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics, Inc., a biotechnology company focused on immunotherapeutic approaches for cancer and is the Founder and President of Bethesda Biomedical Consulting, Inc. Dr. Wigginton previously served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations including anti-CTLA-4/anti-PD-1. He also served in a governance leadership role for discovery efforts in immuno-oncology at BMS.

Prior to joining BMS, Dr. Wigginton served as Director of Clinical Oncology at Merck Research Laboratories, where he led early- and late-stage clinical development teams for small molecules and biologics. Prior to joining industry, Dr. Wigginton held several positions at the National Cancer Institute, Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch, where he led an integrated basic science and early clinical research effort focused on combination immunotherapy. Dr. Wigginton also served previously as President of the Society for Immunotherapy of Cancer (SITC). He received his B.S. in Biology and his M.D. from the University of Michigan.

KURT ROTE, M.B.A.
Director

Kurt Rote co-founded Western Oncolytics and led the company through technology licensing from the University of Pittsburgh, seed and Series A fundraising, and Western’s partnership with Pfizer for WO-12. Kurt previously served as Head of Product Development and Marketing at BiognoSYS AG and in Strategy and Business Development roles at Holcim US Inc.

He holds an M.B.A. from the International Institute for Management Development in Switzerland and a B.S.E from Duke University.

STEVE MOON
Director

Steve Moon, PhD is our Series A Director and a Partner of Premier Partners, Head of the Bio Division. Prior to joining Premier Partners, Dr. Moon worked as a researcher at Samsung Advanced Institute of Technology and invested in life-science and IT startups at Hyundai Venture Investment. He received a B.S. in Fiber and Polymer Science of College of Engineering from Seoul National University, an M.S. in Electrical Engineering and a Ph.D. in Macromolecular Science and Engineering from University of Michigan, and an MBA from University of Cambridge.

GRANT MCFADDEN, Ph.D. Director

Grant McFadden is the director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy and a Professor at Arizona State University. McFadden’s lab pioneered the field of viral immune subversion (also called “anti-immunology”) and is credited with the discovery of a wide spectrum of virus-derived inhibitors of the immune system. He was co-founder and Board member of OncoMyx Therapeutics and has served on advisory boards for numerous companies including Jennerex, DNAtrix and IMV. A recognized international expert, McFadden is a former President of the American Society of Virology, a member of the International Committee on the Taxonomy of Viruses, advisor to the World Health Organization Advisory Committee on Variola Virus Research, and a fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, and the American Academy of Microbiology. He received a Ph.D. in Biochemistry from McGill University.

Scientific Advisory Board

Michael Lotze, M.D.
Nurix Therapeutics, Inc.

Greg Delgoffe, Ph.D.
University of Pittsburgh

Tullia Bruno, Ph.D.
University of Pittsburgh

Jon Wigginton, M.D., Ph.D.
Bright Peak Therapeutics

Clinical Advisory Board

Jonathan Rosenberg, M.D.
Memorial Sloan Kettering Cancer Center

Dmitriy Zamarin, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Jorge Nieva, M.D.
University of Southern California

Mitesh Borad, M.D.
Mayo Clinic

HELENA CHAYE, Ph.D., J.D.

Chief Executive Officer

Helena has over 23 years of experience in the biotechnology industry having held leadership positions in operations, corporate affairs, business development and IP management primarily in oncolytic virotherapy development. Most recently, Helena served as Chief Business Officer at SillaJen Biotherapeutics, Inc. where she managed all operations including corporate and business development strategies, R&D strategy and intellectual property. Prior to joining SillaJen, Helena held the positions of VP of Corporate Affairs & IP at Jennerex Biotherapeutics and the Director of Business Development at MediGene. Helena received her B.S. in Biochemistry and her Ph.D. in Genetics from the University of British Columbia and her J.D. from Dalhousie University.

STEPHEN H. THORNE, Ph.D.

Chief Scientific Officer

Stephen Thorne co-founded Kalivir in 2019 and currently serves as Chief Scientific Officer. He is a leader in the field of oncolytic viral immunotherapy and previously co-founded Western Oncolytics, BioEclipse and Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials.

Stephen was a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London. Stephen has served in post doctorate roles at Surrey University, Cancer Research UK, and Stanford University and has authored more than 100 scientific publications in the field.

JAMES M. BURKE, M.D.

Chief Medical Officer

Dr. James Burke is a University of California, San Francisco trained hematologist and oncologist who has led clinical development of gene therapy and oncolytic viruses for cancer for over 15 years including first in human through Phase 3 studies. Most recently, Dr Burke served as Chief Medical Officer of Sillajen (previously Jennerex) leading Phase 1-3 global development of a vaccinia virus platform for multiple cancers including HCC, RCC, and CRC.

The global Phase 3 registration trial targeting advanced HCC represents one of the largest oncolytic studies conducted to date spanning four continents including North America, Europe, Australia, and Asia. This Phase 3 study was the first oncolytic virus study conducted by a foreign biotech in China and one of only a few OV trials to ever be conducted in mainland China. Aside from Sillajen, Dr Burke led initial Phase 1-2 clinical development of Turnstone’s maraba virus prime-boost oncolytic virus program as CMO through initial studies and fund raising.

Dr Burke started his career at Cell Genesys spearheading early gene and immunotherapy studies including oncolytic adenovirus, lentivirus, AAV, and tumor vaccine programs. In addition to his biotechnology experience, Dr Burke directed studies as a clinical scientist including first in human studies in oncolytic viruses, tumor vaccines, as well as other cancer therapeutics in Phase 1-3 development.

Throughout his career he has had extensive interaction with global regulatory authorities and key academicians, led clinical development of numerous agents, built expert research teams, presented his research findings in key scientific journals and symposia, and led medical discussions and negotiations with external financing entities including venture capital and pharma.

SCHOND GREENWAY

Chief Financial Officer

Schond Greenway joined KaliVir Immunotherapeutics as Chief Financial Officer (CFO) in August 2024. He brings over 25 years of experience in corporate finance and investment analysis, with deep expertise in the life sciences and financial services sectors, particularly in capital markets and corporate financial transactions. Before KaliVir, Schond served as CFO at MindMed (MNMD), where he was responsible for all aspects of corporate finance, investor relations, public relations, and information technology. Before that, he held the CFO position at Avalo Therapeutics (AVTX). Earlier in his career, he held executive leadership roles at Mesoblast Ltd (MESO), Halozyme Therapeutics (HALO), and DURECT Corporation (DRRX). His investment banking career began at Morgan Stanley, and he later became Vice President, Healthcare Desk Analyst at Barclays Capital.

Schond has participated in and advised on transactions totaling over $30 billion during his tenure in investment banking. He also played a critical role in securing more than $1.5 billion in growth equity, debt capital, and R&D funding from biopharmaceutical companies during his leadership tenures at MindMed, Avalo Therapeutics, and other life sciences organizations.

Schond earned a B.S. in Computer Information Systems from Florida A&M University and an MBA from the Darden School of Business at the University of Virginia.

URSULA FRITSCH, PharmD

Chief Regulatory Officer

Ursula has over 30 years of experience in the biotechnology and pharma industry. Ursula has overseen global Regulatory Affairs for a variety of therapeutics across the development life-cycle, with success at the pre-IND, IND, BLA/NDA, Advisory Committee, post-marketing and commercial stages. Ursula has conducted successful regulatory and inspection negotiations, 15 years with oncolytic viruses, with authorities in US, Europe, UK, China, South Korean, Australia, Eastern Europe, Canada, Mexico and South American countries. Ursula has acted as head of regulatory or held positions of increasing responsibility at companies such as Genentech/Roche, Onyx Pharmaceuticals and Jennerex Biotherapeutics. Prior to joining Kalivir, Ursula served as the Chief Regulatory Officer at CG Oncology. Ursula received her Doctorate of Clinical Pharmacy from Creighton University.

ADINA PELUSIO

Chief Development Officer

Ms. Pelusio has more than 20 years of experience in drug development. Before joining KaliVir, she served as Senior Vice President of Clinical Operations at Turnstone Biologics, where she oversaw the advancement of candidate oncolytic viruses, cancer vaccines and adoptive cell therapies into clinical trials. Prior, Ms. Pelusio spent 10 years at SillaJen, Inc. (formerly Jennerex Biotherapeutics) where she led the introduction of oncolytic viruses into 17 countries across Phase I-III clinical trials. She holds an M.S. from the University of Florida and is pursuing an M.P.H. from Harvard University T.H. Chan School of Public Health.

Paul Youm

Vice President, Corporate Development and Alliance Management

Paul Youm is a seasoned attorney and a corporate and business development professional with over 10 years of experience in the biotechnology industry. Prior to joining KaliVir, Paul served as the general counsel and/or head of business development at various biotech companies in immuno-oncology, gene therapy and regenerative medicine, including SillaJen, Inc. (formerly Jennerex), where he held a highly versatile role with cross-functional responsibilities in legal, operations, strategy and corporate development. Paul holds a J.D. equivalent masters degree from Sogang Law School in Korea and a B.S. bachelor’s in biomedical engineering from Duke University.